Grufity logoGrufity logo

GBT

Market Closed

Global Blood Therapeutics Inc

GBT Stock Price

RSI Chart

Valuation

Market Cap

4.6B

Price/Earnings

-14.33

Price/Sales

19.67

Price/Cashflow

-18.53

MarketCap/EBT

-14.13

Price/Sales

Profitability

EBT Margin

-139.26%

Return on Equity

-272.44%

Return on Assets

-37.05%

Fundamentals

Revenue

Revenue (TTM)

234.9M

Revenue Y/Y

50.46%

Revenue Q/Q

29.71%

Earnings

Earnings (TTM)

-322.5M

Earnings Y/Y

-18.51%

Earnings Q/Q

-1.29%

Price Action

Last 7 days

0.5%

Last 30 days

1.0%

Last 90 days

104.5%

Trailing 12 Months

162.2%

Financial Health

Current Ratio

6.88

Debt/Equity

2.94

Debt/Cashflow

-0.72

Investor Care

Shares Dilution (1Y)

8.09%

Diluted EPS (TTM)

-5.01

Peers (Alternatives to Global Blood Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
12.69% 40.17%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
1.16% -37.31%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.98% 19.60%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.97% 52.06%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.42% 24.09%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
4.50% 46.57%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
15.89% 47.00%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-1.99% 2.32%
-18.85
63.29
26.15% -23.38%
3.8B
-
13.27% -45.82%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
15.45% -49.16%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
11.20% -50.29%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
17.07% 137.52%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
- -14.14%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
2.53% -63.72%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-2.84% -83.50%
-0.46
19.11
-77.61% 5.14%

Financials for Global Blood Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue11.4%235211195180165
  S&GA Expenses7.1%303283267248234
  R&D Expenses6.1%227214212194184
Earnings Before Taxes-8.4%-327.06-301.63-302.61-288.74
Net Income-4.2%-322.46-309.58-303.09-277.32-266.21
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets0.1%870870939608615
  Current Assets-5.3%640676802489525
    Cash Equivalents-33.3%261392685383419
  Inventory6.2%6662585248
  Net PPE-3.5%3234353537
Liabilities2.2%752736743299299
  Current Liabilities17.4%9379887473
  Long Term Debt-1.6%348353359192195
    LT Debt, Non Current0.2%247247246150149
Shareholder's Equity-11.7%118134196308316
  Retained Earnings-6.0%-1,453.00-1,371.00-1,300.00-1,200.00-1,130.00
  Additional Paid-In Capital4.6%1,5761,5071,4861,5101,446
Accumulated Depreciation8.5%1817161413
Shares Outstanding3.4%6765656462
Float-888----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations0.0%-249.40-249.41-256.81-233.95-209.34
  Share Based Compensation-0.2%7677797778
Cashflow From Investing-63.9%-390.80-238.391275163
Cashflow From Financing11.1%48243443412380

Risks

What is the probability of a big loss on GBT?

100%


Probability that Global Blood Therapeutics stock will be more than 20% underwater in next one year

87.7%


Probability that Global Blood Therapeutics stock will be more than 30% underwater in next one year.

49.6%


Probability that Global Blood Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GBT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Global Blood Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on GBT

5.2%


7-Year Cumulative Returns

16.2%


5-Year Cumulative Returns

12.5%


3-Year Cumulative Returns

What are the long-term rolling returns for GBT?

FIve years rolling returns for Global Blood Therapeutics.

Which funds bought or sold GBT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
5,888
11,000
0.01%
2022-11-22
Mint Tower Capital Management B.V.
NEW
-
54,000
54,000
-%
2022-11-22
Capital Impact Advisors, LLC
SOLD OFF
-100
-772,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.51
2,833,000
5,361,000
0.01%
2022-11-21
FourThought Financial, LLC
SOLD OFF
-100
-41,000
-
-%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
356,000
356,000
-%
2022-11-17
Telemetry Investments, L.L.C.
NEW
-
218,000
218,000
0.28%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-3,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
UNCHANGED
-
15,000
29,000
-%
2022-11-15
SkyView Investment Advisors, LLC
UNCHANGED
-
-2,000
26,000
0.01%

1–10 of 45

Latest Funds Activity

Are funds buying GBT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own GBT

Global Blood Therapeutics News

Armenian Reporter

Principal Financial Group Inc. Decreases Stake in Global Blood Therapeutics, Inc. (NASDAQ:GBT).109 minutes ago

GuruFocus.com

GBT Fair Value

Recent SEC filings of Global Blood Therapeutics

View All Filings
Date Filed Form Type Document
Oct 17, 2022
15-12G
15-12G
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading

Latest Insider Trading transactions for GBT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-29
Choi Jung
GIFTED
-
-
-73,855
See Remarks
2022-09-27
LOVE TED W
ACQUIRED
299,972
16.4
18,291
President and CEO
2022-09-27
Farrow Jeffrey S
ACQUIRED
387,909
16.4
23,653
Chief Financial Officer
2022-09-27
Choi Jung
ACQUIRED
699,994
7.03589
99,489
See Remarks
2022-09-27
Habibizad Nazila
ACQUIRED
570,391
19.1696
29,755
See Remarks
2022-09-13
LOVE TED W
GIFTED
-
-
17,650
President and CEO
2022-09-13
LOVE TED W
GIFTED
-
-
-35,300
President and CEO
2022-09-09
LOVE TED W
GIFTED
-
-
-221,200
President and CEO
2022-09-01
Krehlik Carrie
SOLD (Taxes)
-242,069
68.15
-3,552
Chief Human Resources Officer

1–10 of 50

Ted W. Love
460
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

GBT Income Statement

2022-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues [Abstract]    
Product sales, net$ 71,550$ 47,555$ 126,710$ 86,598
Costs and operating expenses:    
Cost of sales1,4137482,4681,332
Research and development64,77551,784117,608102,641
Selling, general and administrative81,08861,093155,622120,059
Total costs and operating expenses147,276113,625275,698224,032
Loss from operations(75,726)(66,070)(148,988)(137,434)
Other income (expense):    
Interest income1,6641642,164493
Interest expense(8,402)(3,677)(16,607)(7,366)
Other income (expense), net18621(100)(62)
Total other income (expense,), net(6,552)(3,492)(14,543)(6,935)
Loss before income taxes(82,278)(69,562)(163,531)(144,369)
Provision for income taxes19230362153
Net loss(82,470)(69,592)(163,893)(144,522)
Other comprehensive loss:    
Net unrealized gain on marketable securities, net of tax(1,711)(78)(3,626)(259)
Cumulative translation adjustment(300)259(446)259
Total other comprehensive expense, net(2,011)181(4,072)0
Comprehensive loss$ (84,481)$ (69,411)$ (167,965)$ (144,522)
Basic net loss per common share$ (1.26)$ (1.12)$ (2.51)$ (2.32)
Diluted net loss per common share$ (1.26)$ (1.12)$ (2.51)$ (2.32)
Weighted-average number of shares used in computing basic net loss per common share65,594,79262,312,41865,220,51862,207,328
Weighted-average number of shares used in computing diluted net loss per common share65,594,79262,312,41865,220,51862,207,328

GBT Balance Sheet

2022-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 261,152$ 684,717
Short-term marketable securities256,0060
Accounts receivable, net29,76528,800
Inventories65,81658,202
Prepaid expenses and other current assets27,27230,251
Total current assets640,011801,970
Long-term marketable securities146,86350,057
Property and equipment, net32,42534,918
Operating lease right-of-use assets46,49748,015
Restricted cash2,4322,436
Other assets, noncurrent2,2141,812
Total assets870,442939,208
Current liabilities:  
Accounts payable8,26015,097
Accrued liabilities53,26639,297
Accrued compensation25,18727,712
Other liabilities, current6,3795,892
Total current liabilities93,09287,998
Long-term debt, net247,130246,352
Convertible debt, net334,815334,089
Operating lease liabilities, noncurrent70,32273,506
Other liabilities, noncurrent6,723853
Total liabilities752,082742,798
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of June 30, 2022 (unaudited) and December 31, 2021; no shares issued and outstanding00
Common stock, $0.001 par value, 150,000,000 shares authorized as of June 30, 2022 (unaudited) and December 31, 2021, respectively; 67,257,761 and 64,636,641 shares issued and outstanding as of June 30, 2022 (unaudited) and December 31, 2021, respectively6765
Additional paid-in capital1,575,7191,485,805
Accumulated other comprehensive income(3,973)100
Accumulated deficit(1,453,453)(1,289,560)
Total stockholders' equity118,360196,410
Total liabilities and stockholders' equity$ 870,442$ 939,208